Vanguard Group Inc Keros Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,856,418 shares of KROS stock, worth $101 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,856,418
Previous 1,757,120
5.65%
Holding current value
$101 Million
Previous $80.3 Million
34.25%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$136 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$103 Million0.19% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$82.5 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$82 Million0.01% of portfolio
-
State Street Corp Boston, MA1.11MShares$60.3 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.39B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...